Evaluation of the Diagnostic Performance of the TestNPass DM-DIV for SARS-CoV-2 Using a Nasopharyngeal Sample

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-30

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COVID-19 pandemic has created a major global health crisis that requires a rapid and effective response, particularly in the field of diagnostics.

The first tests used, based on PCR (polymerase chain reaction) performed through a deep nasopharyngeal swab, have shown their limitations in controlling the epidemic. The current need is to develop new tests that are rapid, affordable and easy to use, and that can be used on a large scale in outpatient settings to reduce the burden on healthcare teams. In addition, a test that is easy to produce and can be stored at room temperature would help overcome the significant logistical challenge of regularly testing the general population to specifically isolate carriers of the virus.

In this context, an innovative test called "TestNPass" has been developed. TestNPass is a rapid and affordable antigen test for screening and diagnosis that provides a secure digital passport and/or QR code upon request.

Our aim is to evaluate the diagnostic performance of TestNPass using nasopharyngeal swabs for the detection of SARS-CoV-2 infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample

NCT04654442

Covid19 SARS-CoV-2

COMPLETED

COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19

NCT04703140

COVID-19 SARS-CoV-2

TERMINATED NA

Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test

NCT04609969

Covid19 SARS-CoV-2 Infection

COMPLETED NA

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva

NCT04578509

SARS-CoV-2 Infection COVID-19

COMPLETED

Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19

NCT04510454

Cancer COVID

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The COVID-19 pandemic and the global spread of SARS-CoV-2 are historic events in terms of their magnitude and the collective response they have elicited from medical teams, governments and the general public. This situation requires a rapid and effective response to find solutions, particularly in the field of diagnostics.

While the initial tests used were based on PCR (polymerase chain reaction) and deep nasopharyngeal swabs, this approach has shown its limitations in controlling the epidemic. The significant logistical resources required for its implementation limit its large-scale use beyond what is currently being done. In addition, deep nasopharyngeal sampling is not feasible for repeated testing of healthy populations as part of primary screening.

The current need is to develop new point-of-care (PoC) testing methods that are rapid, affordable and easy to use. These characteristics would allow mass use in outpatient settings, reducing the burden on healthcare teams. In addition, a test that is easy to produce and can be stored at room temperature would address the immense logistical challenge of regularly testing the general population to specifically isolate virus carriers.

In this context, an innovative test called "TestNPass" has been developed by the Grenoble-based start-up company Grapheal. TestNPass is a rapid and low-cost antigen test for screening and diagnosis that delivers a secure digital passport and/or QR code on request. This type of device could also be used to detect various antigens, such as those of influenza, streptococcus A or shingles.

Our objective in this study is to evaluate the diagnostic performance of an in vitro diagnostic medical device (IVD) for the detection of SARS-CoV-2 infection using a nasopharyngeal swab. To achieve this, we will take an additional nasopharyngeal swab sample immediately after the sample taken as part of routine health care.

A total of 400 adult participants who require a nasopharyngeal swab for their medical care will be enrolled in this study. The only additional procedure involved in the study is the collection of a second nasopharyngeal swab. The study consists of a single visit (1 day).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases: 100 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19

Diagnostic Test: TestNPass Patients will undergo nasopharyngeal sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).

Group Type ACTIVE_COMPARATOR

nasopharyngeal swab.

Intervention Type DIAGNOSTIC_TEST

The only additional procedure related to the study is a nasopharyngeal swab.

Controls 300 controls : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19

Diagnostic Test: TestNPass Patients will undergo nasopharyngeal sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).

Group Type SHAM_COMPARATOR

nasopharyngeal swab.

Intervention Type DIAGNOSTIC_TEST

The only additional procedure related to the study is a nasopharyngeal swab.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nasopharyngeal swab.

The only additional procedure related to the study is a nasopharyngeal swab.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults ≥18 years of age
* Consulting or hospitalized at the University Hospital of Grenoble Alpes, for whom a SARS-CoV-2 RT-PCR test via nasal swab is considered due to symptoms or context (hospitalization in a double room, ongoing epidemic outbreak)
* Having provided informed consent to participate in the study.
* Patient having the rights to French social insurance

Exclusion Criteria

* Contraindication to nasopharyngeal swabbing:
* Anatomical abnormalities or medical conditions:
* Severe nasal septum deviation or nasal polyps
* History of recent nasal or facial surgery
* Severe sinusitis or nasal infections
* Bleeding disorders
* Extreme sensitivity or phobias related to medical procedures
* Participation in an exclusion period of another SARS-CoV-2 performance study: Minors

Pregnant or breastfeeding women, Individuals under guardianship or curatorship, Individuals deprived of liberty or involuntarily hospitalized, Individuals under administrative or judicial supervision, Persons unable to provide informed consent

* Staff with a hierarchical relationship with the principal investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No